Latest news on Laboratorytalk categorised by supplier
Acrongenomics
Address:
14 Rue Kleberg
Geneva
CH-1201
Switzerland
Telephone: (Switzerland) +41 22 716 5300
http://www.acrongen.com
Our RSS feed for news from Acrongenomics
Request to receive our free email newsletter each week
Listing of all 20 news releases from Acrongenomics:
Acrongenomics to buy Molecular Vision
Acrongenomics has signed a letter of intent to buy 100% of Molecular Vision, a private UK company that specialises in the development of miniaturised point-of-care (POC) medical diagnostic devices
News from Acrongenomics (22 November 2007)
Creating a prototype diagnostic device
Acrongenomics, Molecular Vision, and Pearson Matthews join forces to design a fully-manufacturable, prototype, point-of-care medical diagnostic device for detecting kidney and cardiac biomarkers
News from Acrongenomics (29 June 2007)
Manolis joins Acrongenomics board of directors
Acrongenomics, a publicly traded life sciences company, reporst that Evan Manolis has joined its board of directors and scientific committee
News from Acrongenomics (10 May 2007)
Prestigious award from the UK Royal Society
Acrongenomics's partner Molecular Vision has been successful in winning the £250,000 Royal Society Brian Mercer Award for Innovation 2007
News from Acrongenomics (10 May 2007)
BioLED lab on a chip successfully demonstrated
Technical background article The demonstrated device used two forms of detection utilising chemiluminescence and fluorescence to detect different markers of interest
News from Acrongenomics (10 May 2007)
BioLED adapted for chemiluminescence, fluorescence
Acrongenomics and Molecular Vision focus on providing low-cost, easy to use and readily portable point-of-care devices for medical testing that will give accurate diagnosis in minutes
News from Acrongenomics (10 May 2007)
£440,000 award from the UK National Health Service
The HTD scheme, which provides 50% funding, aims to stimulate new and innovative health care technologies designed to improve significantly the quality of healthcare in the United Kingdom
News from Acrongenomics (10 October 2006)
On track to meet targets for BioLED technology
Acrongenomics and Molecular Vision present an R+D update of their collaboration, following the meeting of the project's steering committee on 28 July 2006 at Molecular Vision's site in London
News from Acrongenomics (10 October 2006)
Accelerating low-cost point-of-care diagnostics
Acrongenomics and Molecular Vision present an R+D update of their joint collaboration, following the meeting of the project's steering committee on 28 July 2006 at Molecular Vision's site in London
News from Acrongenomics ( 3 August 2006)
Joint development agreement with Molecular Vision
Acrongenomics signs a US$6.5 million (£3.45million) joint development agreement with Molecular Vision to offer novel point-of-care solutions through the unique BioLED technology
News from Acrongenomics (24 May 2006)
Memorandum of understanding with Molecular Vision
Companies to embark on joint R+D to develop and commercialise low cost, easy-to-use and readily portable point-of-care (POC) diagnostic devices for medical testing
News from Acrongenomics (24 May 2006)
Acrongenomics in deal with Molecular Vision
Acrongenomics enters into memorandum of understanding with Molecular Vision, an Imperial Innovations spin-out company, to develop point-of-care diagnostic devices
News from Acrongenomics (31 March 2006)
$4million to fund ongoing operations
Acrongenomics will use the net proceeds for the ongoing development of the Nano-Jeta platform as well as general corporate purposes
News from Acrongenomics (29 December 2005)
Nanotechnology platform gets marketing boost
KGMC will secure publications of this 'breakthrough technology' in respected medical and scientific journals and identify ideal partners to commercialise the technology
News from Acrongenomics (11 November 2005)
This is the dawning of the age of nanobiotech
Technical background article The global scientific community, seeking simpler, faster, cheaper diagnostics, is turning to nanoscience to overcome current limitations and empower a revolutionary new era in science and technology
News from Acrongenomics (26 October 2005)
PCR pilot kits for DNA/RNA quantification
Pilot kits allow for 24 tests to be performed and contain a certificate of analysis, comprehensive manual, general mix, pre-mix, master mix, and new mathematical model
News from Acrongenomics ( 7 October 2005)
Testing against the 'gold standard' real time PCR
Technical background article Acrongenomics is currently conducting a clinical comparison study of its Nano-Jeta real time PCR by the detection of Ep-CAM, HER1, HER2, vEGF and beta-actin genes in peripheral blood samples
News from Acrongenomics ( 7 October 2005)
First clinical validation study on Nano-Jeta
Technical background article The objectives of the study were to validate Nano-Jeta via the detection of Ep-CAM gene and beta-actin and to evaluate the technology in comparison to conventional real time PCR methodology
News from Acrongenomics ( 7 October 2005)
Cancer detection kit provides enhanced performance
Nanotechnology is beginning to generate substantial new insights into how biological systems function and is believed to hold potential advances in both the pharmaceuticals and health care industries
News from Acrongenomics ( 7 October 2005)
Ultra-fast nucleic acid amplification 'beats PCR'
Technology claims advantages over real time PCR by achieving nucleic acid amplification, detection and quantification in two minutes with the option for isothermal and non-isothermal protocols
News from Acrongenomics ( 3 October 2005)
